MD B4: The influence of prednisolone treatment on split formation in the human skin organ culture model for pemphigus vulgaris

Pemphigus vulgaris (PV) is an organ-specific autoimmune blistering disease of the skin. It is characterized and caused by a pathological formation of circulating autoantibodies against desmoglein 1 (Dsg1) and/or Dsg3. Binding of anti-Dsg1 and anti-Dsg3-autoantibodies disrupts the cell-cell adhesion between keratinocytes, resulting in intraepidermal blistering (acantholysis) in the epidermis and mucous membranes alike (Hammers and Stanley, 2016).

On top of the visible clinical symptoms, intraepithelial split formation in histological sections can be observed. Current therapeutic approaches involve high dose, systemic corticosteroids, immunoapheresis of circulating antibodies and intravenous administration of immunoglobulins, including the anti-CD20-antibody Rituximab (Hammers and Stanley, 2016). All these therapeutic options target general immunosuppression. In my project, I will observe the effects of prednisolone treatment in the human skin organ culture model for PV, which was previously established in the Hundt lab (Burmester et al.,2019).

Two sets of data with a different outcome were achieved in the project-related previous work. The question we would like to answer is whether this difference is due to a different dosage of prednisolone. For this purpose, we will perform new human skin organ cultures for PV. The aim is to clarify if there is a definite effect of prednisolone as a treatment option for PV in the HSOC model or not.